Advertisement

Association of serum MMP-9 with autoantibodies against oxidized LDL

      Abstract

      Monocyte-derived macrophages in atherosclerotic plaques secrete matrix metalloproteinases (MMPs), which may contribute to plaque rupture. There has been much speculation as to which factors precipitate in the arterial inflammation. Oxidized low density lipoprotein (oxLDL) has been suggested to have proinflammatory properties, and it has been shown to increase matrix metalloproteinase-9 (MMP-9) secretion by macrophages in vitro. We determined serum MMP-9 concentration and autoantibodies against oxLDL by ELISA in men with angina pectoris (n=243) and age-matched controls (n=238). The association between serum MMP-9 concentration and autoantibodies against oxLDL was evaluated. Autoantibody level against oxLDL, expressed in optical density units, was significantly higher in subjects with angina pectoris compared to controls (0.100±0.064 versus 0.088±0.051, respectively, P=0.030), but serum levels of MMP-9 did not differ significantly between these groups (54.2±29.9 versus 50.6±23.1 μg/l). However, autoantibodies against oxLDL correlated positively with serum MMP-9 (r=0.21, P<0.001). In a multiple regression model (including age, diastolic blood pressure, cholesterol, HDL cholesterol, triglycerides, BMI, smoking and MMP-9) serum MMP-9 (β=0.200, P<0.001) and smoking (β=0.179, P<0.001) were significantly associated with autoantibodies against oxLDL. In conclusion, autoantibodies against oxLDL were positively associated with angina pectoris and serum MMP-9. Since autoantibody level against oxLDL could be expected to reflect the degree of oxLDL in the vessel wall, our results suggest that oxLDL is associated with MMP-9 in vivo.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Galis Z.S.
        • Sukhova G.K.
        • Lark M.W.
        • Libby P.
        Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques.
        J. Clin. Invest. 1994; 94: 2493-2503
        • Celentano D.C.
        • Frishman W.H.
        Matrix metalloproteinases and coronary artery disease: a novel therapeutic target.
        J. Clin. Pharmacol. 1997; 37: 991-1000
        • Schroeder A.P.
        • Falk E.
        Pathophysiology and inflammatory aspects of plaque rupture.
        Cardiol. Clin. 1996; 14: 211-220
        • Shah P.K.
        • Falk E.
        • Badimon J.J.
        • et al.
        Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques.
        Circulation. 1995; 95: 1565-1569
        • Davies M.J.
        Reactive oxygen species, metalloproteinases, and plaque stability.
        Circulation. 1998; 97: 2382-2383
        • Brown D.L.
        • Hibbs M.S.
        • Kearney M.
        • Loushin C.
        • Isner J.M.
        Identification of 92-kD gelatinase in human coronary atherosclerotic lesions: association of active enzyme synthesis with unstable angina.
        Circulation. 1995; 91: 2125-2131
        • Sorbi D.
        • French D.L.
        • Nuovo G.J.
        • Kew R.R.
        • Arbeit L.A.
        • Gruber B.L.
        Elevated levels of 92-kd type IV collagenase (matrix metalloproteinase 9) in giant cell arteritis.
        Arthritis Rheum. 1996; 39: 1747-1753
        • Kalela A.
        • Pönniö M.
        • Koivu T.A.
        • Höyhtyä M.
        • Huhtala H.
        • Sillanaukee P.
        • Nikkari S.T.
        Association of serum sialic acid and MMP-9 with lipids and inflammatory markers.
        Eur. J. Clin. Invest. 2000; 30: 99-104
        • Xu X.P.
        • Meisel S.R.
        • Ong J.M.
        • Kaul S.
        • Cercek B.
        • Rajavashisth T.B.
        • Sharifi B.
        • Shah P.K.
        Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages.
        Circulation. 1999; 99: 993-998
        • Palinski W.
        • Rosenfeld M.E.
        • Yla-Herttuala S.
        • Gurtner G.C.
        • Socher S.S.
        • Butler S.W.
        • Parthasarathy S.
        • Carew T.E.
        • Steinberg D.
        • Witztum J.L.
        Low density lipoprotein undergoes oxidative modification in vivo.
        Proc. Natl. Acad. Sci. U.S.A. 1989; 86: 1372-1376
        • Ylä-Herttuala S.
        • Palinski W.
        • Butler S.W.
        • Picard S.
        • Steinberg D.
        • Witztum J.L.
        Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL.
        Arterioscler. Thromb. 1994; 14: 32-40
        • Lehtimäki T.
        • Lehtinen S.
        • Solakivi T.
        • Nikkilä M.
        • Jaakkola O.
        • Jokela H.
        • Ylä-Herttuala S.
        • Luoma J.S.
        • Koivula T.
        • Nikkari T.
        Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease.
        Arterioscler. Thromb. Vasc. Biol. 1999; 19: 23-27
        • Wu R.
        • Nityanand S.
        • Berglund L.
        • Lithell H.
        • Holm G.
        • Lefvert A.K.
        Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction.
        Arterioscler. Thromb. Vasc. Biol. 1997; 17: 3159-3163
        • Eber B.
        • Schumacher M.
        • Tatzber F.
        • Kaufmann P.
        • Luha O.
        • Esterbauer H.
        • Klein W.
        Autoantibodies to oxidized low density lipoproteins in restenosis following coronary angioplasty.
        Cardiology. 1994; 84: 310-315
        • Soini Y.
        • Hurskainen T.
        • Höyhtyä M.
        • Oikarinen A.
        • Autio-Harmainen H.
        72 kD and 92 kD type IV collagenase, type IV collagen, and laminin mRNAs in breast cancer: a study by in situ hybridization.
        J. Histochem. Cytochem. 1994; 42: 945-951
        • Uusitupa M.I.
        • Niskanen L.
        • Luoma J.
        • Vilja P.
        • Mercuri M.
        • Rauramaa R.
        • Ylä-Herttuala S.
        Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus.
        Arterioscler. Thromb. Vasc. Biol. 1996; 16: 1236-1242
        • WHO MONICA Project Principal Investigators
        The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration.
        J. Clin. Epidemiol. 1988; 41: 105-114
        • Evans P.J.
        • Smith C.
        • Mitchinson M.J.
        • Halliwell B.
        Metal ion release from mechanically disrupted human arterial wall. Implications for the development of atherosclerosis.
        Free Radic. Res. 1995; 23: 465-469
        • Nikkari S.T.
        • Höyhtyä M.
        • Isola J.
        • Nikkari T.
        Macrophages contain 92-kd gelatinase (MMP-9) at the site of degenerated internal elastic lamina in temporal arteritis.
        Am. J. Pathol. 1996; 149: 1427-1433
        • Jovinge S.
        • Ares M.P.
        • Kallin B.
        • Nilsson J.
        Human monocytes/macrophages release TNF-alpha in response to Ox-LDL.
        Arterioscler. Thromb. Vasc. Biol. 1996; 16: 1573-1579
        • George S.J.
        Tissue inhibitors of metalloproteinases and metalloproteinases in atherosclerosis.
        Curr. Opin. Lipidol. 1998; 9: 413-423
        • Chen N.G.
        • Sarabia S.F.
        • Malloy P.J.
        • Zhao X.Y.
        • Feldman D.
        • Reaven G.M.
        PPARgamma agonists enhance human vascular endothelial adhesiveness by increasing ICAM-1 expression.
        Biochem. Biophys. Res. Commun. 1999; 263: 718-722
        • Sakai M.
        • Miyazaki A.
        • Hakamata H.
        • Sato Y.
        • Matsumura T.
        • Kobori S.
        • Shichiri M.
        • Horiuchi S.
        Lysophosphatidylcholine potentiates the mitogenic activity of modified LDL for human monocyte-derived macrophages.
        Arterioscler. Thromb. Vasc. Biol. 1996; 16: 600-605
        • Quinn M.T.
        • Parthasarathy S.
        • Fong L.G.
        • Steinberg D.
        Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis.
        Proc. Natl. Acad. Sci. U.S.A. 1987; 84: 2995-2998
        • Erkkilä A.T.
        • Narvanen O.
        • Lehto S.
        • Uusitupa M.I.
        • Ylä-Herttuala S.
        Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease.
        Arterioscler. Thromb. Vasc. Biol. 2000; 20: 204-209
        • Maggi E.
        • Finardi G.
        • Poli M.
        • Bollati P.
        • Filipponi M.
        • Stefano P.L.
        • Paolini G.
        • Grossi A.
        • Clot P.
        • Albano E.
        • Bellomo G.
        Specificity of autoantibodies against oxidized LDL as an additional marker for atherosclerotic risk.
        Coron. Artery Dis. 1993; 4: 1119-1122
        • Schumacher M.
        • Eber B.
        • Tatzber F.
        • Kaufmann P.
        • Halwachs G.
        • Fruhwald F.M.
        • Zweiker R.
        • Esterbauer H.
        • Klein W.
        Transient reduction of autoantibodies against oxidized LDL in patients with acute myocardial infarction.
        Free Radic. Biol. Med. 1995; 18: 1087-1091
        • van de Vijver L.P.
        • Steyger R.
        • van Poppel G.
        • Boer J.M.
        • Kruijssen D.A.
        • Seidell J.C.
        • Princen H.M.
        Autoantibodies against MDA-LDL in subjects with severe and minor atherosclerosis and healthy population controls.
        Atherosclerosis. 1996; 122: 245-253
        • Hulthe J.
        • Wikstrand J.
        • Lidell A.
        • Wendelhag I.
        • Hansson G.K.
        • Wiklund O.
        Antibody titers against oxidized LDL are not elevated in patients with familial hypercholesterolemia.
        Arterioscler. Thromb. Vasc. Biol. 1998; 18: 1203-1211
        • Shoji T.
        • Nishizawa Y.
        • Fukumoto M.
        • Shimamura K.
        • Kimura J.
        • Kanda H.
        • Emoto M.
        • Kawagishi T.
        • Morii H.
        Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects.
        Atherosclerosis. 2000; 148: 171-177
        • Fukumoto M.
        • Shoji T.
        • Emoto M.
        • Kawagishi T.
        • Okuno Y.
        • Nishizawa Y.
        Antibodies against oxidized LDL and carotid artery intima-media thickness in a healthy population.
        Arterioscler. Thromb. Vasc. Biol. 2000; 20: 703-707
        • Palinski W.
        • Miller E.
        • Witztum J.L.
        Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis.
        Proc. Natl. Acad. Sci. U.S.A. 1995; 92: 821-825